OPKO Health (NASDAQ:OPK) Reaches New 52-Week High – Here’s Why

OPKO Health, Inc. (NASDAQ:OPK)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $1.73 and last traded at $1.65, with a volume of 34529633 shares. The stock had previously closed at $1.24.

Key OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Q2 results significantly exceeded estimates. OPKO reported an adjusted loss of $0.01 per share, versus the consensus estimate of a $0.08 loss and a $0.19 loss in the year-earlier quarter. Revenue increased 4.3% year over year to $163.6 million, well above the $131.2 million analyst forecast. Why Opko Health Stock Surged by 33% on Tuesday
• Positive Sentiment: Management raised its 2026 revenue outlook. OPKO now expects full-year revenue of $560 million to $585 million, above the previous analyst consensus of approximately $536 million. The outlook reflects pharmaceutical growth, contributions from Nicoya and tighter cost control. OPKO 2026 Revenue Guidance
• Positive Sentiment: The pipeline added potential longer-term catalysts. OPKO’s ModeX unit presented data on multispecific antibody programs designed to target in-vivo CAR-T applications, with Phase 1 studies potentially beginning later this year or in early 2027. The company also continues preparing MDX3001 for clinical development. OPKO Second Quarter 2026 Business Highlights
• Neutral Sentiment: Near-term revenue guidance was broadly consistent with expectations. OPKO forecast third-quarter revenue of $131 million to $142 million, compared with an analyst estimate of $134.8 million, suggesting continued growth but limited immediate upside from the quarterly outlook. OPKO Health Reports Second Quarter Results
• Negative Sentiment: OPKO remains unprofitable. Although the quarterly loss narrowed substantially, the company still posted negative net margins and analysts expect a loss for the full year. Future performance also depends on execution of its pipeline and continued pharmaceutical growth.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $1.55.

OPKO Health Price Performance

The company’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.27. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. The company has a market capitalization of $1.25 billion, a P/E ratio of -18.33 and a beta of 1.48.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. The business had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.79%. OPKO Health’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.19) EPS. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.29 EPS for the current year.

Institutional Trading of OPKO Health

Several hedge funds have recently added to or reduced their stakes in the company. Comerica Bank grew its holdings in OPKO Health by 7.1% in the 4th quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 8,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in OPKO Health by 4.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock worth $262,000 after buying an additional 8,954 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of OPKO Health by 11.2% during the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock worth $183,000 after buying an additional 13,912 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of OPKO Health by 11.4% during the fourth quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock worth $201,000 after buying an additional 16,329 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of OPKO Health by 75.0% in the second quarter. Prudential Financial Inc. now owns 46,842 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 20,076 shares during the period. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.